Navigation Links
Exosome Diagnostics and DxS Diagnostic Innovations Collaborate to Develop Blood-Based Tests for Key Cancer Mutations
Date:6/22/2009

NEW YORK, June 22 /PRNewswire/ -- Exosome Diagnostics, Inc. ("ExosomeDX") and DxS Ltd. ("DxS") today announced that they will collaborate on the development of blood-based companion diagnostics for key cancer gene mutations, such as KRAS, BRAF and EGFR. The collaboration will use DxS' industry leading Scorpions(R) real-time PCR Mutation Test Kits in conjunction with ExosomeDX's xOS(TM) technology which harvests high-quality nucleic acids from blood exosomes.

The collaboration will initially focus on developing blood-based measurement of KRAS, BRAF, EGFR and other key mutations for predicting patient response to targeted therapies. Blood-based mutation measurement is particularly valuable in circumstances where tissue bioavailability is limited such as in lung, pancreatic and ovarian cancers.

Exosomes are small microvesicles precipitously shed by all solid tumors into blood. They contain virtually the entire cancer tumor transcriptome. In studies, ExosomeDX has identified most mRNA and miRNA in circulating tumor derived exosomes, all protected in the exosome lipid bi-layer from any blood-based RNase. Initial findings were published in the December 2008 issue of Nature Cell Biology.

"There are over 180 companies investigating over 370 different molecular targeted cancer therapies, many of which will require high-quality, molecular companion diagnostics," said James McCullough, Chief Executive Officer Exosome Diagnostics. "Teaming with the world leader in this space is a critical step in providing a solution for pharmaceutical companies, researchers and clinicians to measure the key mutations DxS Scorpion probes target directly from blood."

"Combining the ability to pull high-quality mutations from a simple blood draw with the unparalleled sensitivity and specificity of our Scorpion assays will provide our pharmaceutical and research customers with an ideal solution in personalized medicine," said Dr. Stephen Little, Chief Executive Officer of DxS.

About DxS

DxS is a personalised medicine company providing molecular diagnostics to aid doctors and drug companies in selecting therapies for patients. DxS offers products, technology and services to the healthcare industry to enable the delivery of safe and effective medicines. Working predominantly in the field of cancer, DxS has a range of companion diagnostic and research kits that detect mutations in oncogenes. For more information, visit www.dxsdiagnostics.com.

About Exosome Diagnostics

Exosome Diagnostics is a developer of proprietary non-invasive, molecular diagnostic tests. The company's core technology is based on discoveries by Harvard and Massachusetts General Hospital researchers that circulating nanovesicles in blood and urine called exosomes contain unique genetic markers that can be reliably harvested for personalized medicine cancer diagnostics. For more information, visit www.exosomedx.com.


'/>"/>
SOURCE Exosome Diagnostics, Inc.; DxS Diagnostic Innovations
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Exosome Diagnostics Announces Additions to Management Team
2. Exosome Diagnostics Appoints Johan Skog, Ph.D., as Director of Genetics Research
3. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
4. Strategic Diagnostics Updates Roth Conference Presentation Time
5. Alliance for Medical Devices, Instrumentation and Diagnostics formed between Fraunhofer Center for Manufacturing Innovation and Boston University
6. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
7. Indivumed Supports Roche Diagnostics With Immunohistochemistry Services and Clinical Specimens for Biomarker Discovery and Drug Development
8. Quest Diagnostics to Speak at the 2007 UBS Global Life Sciences Conference
9. BoVir(R) Named Best New Veterinary Diagnostics Product in International Animal Pharm Awards
10. Enigma Diagnostics Announces a European Commission Award of EUR3 Million to Fund the Development of a Point of Care Platform for the Rapid Diagnosis of Influenza Infections
11. MedAssets Supply Chain Systems Selects Siemens Medical Solutions Diagnostics for Chemistry, Automation and Immunoassay Solutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... LONDON , Feb. 9, 2016 /PRNewswire/ ... (PTP1B) Inhibitors-Pipeline Insights, 2016", report provides in ... their development activities around the Protein-Tyrosine Phosphatase ... the product profiles in various stages of ... Phase II, Phase III and Preregistration. Report ...
(Date:2/8/2016)... Should antibiotic bone cement products be used ... infection after standard total hip or knee replacement surgery? ... have been fielding a lot lately. "Antibiotic ... --> "Antibiotic Bone Cement: Fighting ... --> While there isn,t a simple answer, ECRI ...
(Date:2/8/2016)... , February 8, 2016 ... Oncology Private Limited, an innovation-driven oncology company developing ... and less toxic, today announced that chairman emeritus ... has invested in the company as part of ... round, joining existing investors Navam Capital and Aarin ...
(Date:2/8/2016)... ... 2016 , ... Thomas J. Todorow has joined the University ... Corporate Services and the Chief Financial Officer at The Children’s Hospital of Philadelphia ... Care Contracting, Supply Chain, and Investments. , Prior to joining CHOP and The ...
Breaking Biology Technology:
(Date:1/18/2016)... SAN JOSE, Calif. , Jan. 18, 2016 ... storage security software that simplifies the use and ... a technology and go-to-market partnership with American Cyber.  ... "American Cyber brings extensive experience leading transformational C4ISR ... missions implementing and integrating the latest proven technology ...
(Date:1/13/2016)... 13, 2016 --> ... new market report titled - Biometric Sensors Market - Global ... - 2023. According to the report, the global biometric sensors market was ... to reach US$1,625.8 mn by 2023, expanding at a ... of volume, the biometric sensors market is expected to ...
(Date:1/11/2016)... 11, 2016 Synaptics Incorporated (NASDAQ: SYNA ... announced that its ClearPad ® TouchView ™ ... two separate categories in the 8 th Annual ... Technology Breakthrough. The Synaptics ® TDDI solution enables ... chain, thinner devices, brighter displays and borderless designs. ...
Breaking Biology News(10 mins):